{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T16:19:03Z","timestamp":1788884343370,"version":"build-2803163510"},"reference-count":189,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T00:00:00Z","timestamp":1618444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>This article discusses the role that melatonin may have in the prevention and treatment of Parkinson\u2019s disease (PD). In parkinsonian patients circulating melatonin levels are consistently disrupted and the potential therapeutic value of melatonin on sleep disorders in PD was examined in a limited number of clinical studies using 2\u20135\u00a0mg\/day melatonin at bedtime. The low levels of melatonin MT1 and MT2 receptor density in substantia nigra and amygdala found in PD patients supported the hypothesis that the altered sleep\/wake cycle seen in PD could be due to a disrupted melatonergic system. Motor symptomatology is seen in PD patients when about 75% of the dopaminergic cells in the substantia nigra pars compacta region degenerate. Nevertheless, symptoms like rapid eye movement (REM) sleep behavior disorder (RBD), hyposmia or depression may precede the onset of motor symptoms in PD for years and are index of worse prognosis. Indeed, RBD patients may evolve to an \u03b1-synucleinopathy within 10\u00a0years of RBD onset. Daily bedtime administration of 3\u201312\u00a0mg of melatonin has been demonstrated effective in RDB treatment and may halt neurodegeneration to PD. In studies on animal models of PD melatonin was effective to curtail symptomatology in doses that allometrically projected to humans were in the 40\u2013100\u00a0mg\/day range, rarely employed clinically. Therefore, double-blind, placebo-controlled clinical studies are urgently needed in this respect.<\/jats:p>","DOI":"10.3389\/fphar.2021.650597","type":"journal-article","created":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T00:41:21Z","timestamp":1618533681000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":61,"title":["Melatonin as a Chronobiotic and Cytoprotective Agent in Parkinson\u2019s Disease"],"prefix":"10.3389","volume":"12","author":[{"given":"Santiago","family":"P\u00e9rez-Lloret","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel P.","family":"Cardinali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,4,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/life10070101","article-title":"Interaction of oxidative stress and misfolded proteins in the mechanism of neurodegeneration","volume":"10","author":"Abramov","year":"2020","journal-title":"Life. Basel."},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/s0024-3205(96)00606-6","article-title":"Melatonin is protective against MPTP-induced striatal and hippocampal lesions","volume":"60","author":"Acu\u00f1a-Castroviejo","year":"1996","journal-title":"Life Sci."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.1007\/s00018-014-1579-2","article-title":"Extrapineal melatonin: sources, regulation, and potential functions","volume":"71","author":"Acu\u00f1a-Castroviejo","year":"2014","journal-title":"Cell. Mol. Life Sci."},{"key":"B4","article-title":"Melatonin MT1 and MT2 receptor expression in Parkinson\u2019s disease","volume":"16","author":"Adi","year":"","journal-title":"Med. Sci. Monit."},{"key":"B5","first-page":"BR61","article-title":"Melatonin MT1 and MT2 receptor expression in Parkinson\u2019s disease","volume":"16","author":"Adi","year":"","journal-title":"Med. Sci. Monit."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/S0024-3205(01)01480-1","article-title":"Melatonin reverses neurochemical alterations induced by 6-OHDA in rat striatum","volume":"70","author":"Aguiar","year":"2002","journal-title":"Life Sci."},{"key":"B7","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.parkreldis.2020.03.029","article-title":"Prolonged-release melatonin in Parkinson\u2019s disease patients with a poor sleep quality: a randomized trial","volume":"75","author":"Ahn","year":"2020","journal-title":"Park. Relat. Disord."},{"key":"B8","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.ejim.2006.02.020","article-title":"Characteristic findings on 24-h ambulatory blood pressure monitoring in a series of patients with Parkinson\u2019s disease","volume":"17","author":"Ahsan Ejaz","year":"2006","journal-title":"Eur. J. Intern. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1080\/17446651.2019.1631158","article-title":"New insights into the function of melatonin and its role in metabolic disturbances","volume":"14","author":"Amaral","year":"2019","journal-title":"Expert Rev. Endocrinol. Metab."},{"key":"B10","volume-title":"The international classification of sleep disorders","year":"2015"},{"key":"B11","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1093\/sleep\/14.6.496","article-title":"Periodic limb movements in sleep in community-dwelling elderly","volume":"14","author":"Ancoli-Israel","year":"1991","journal-title":"Sleep"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-016-0052-2","article-title":"Pharmacokinetics of oral and intravenous melatonin in healthy volunteers","volume":"17","author":"Andersen","year":"2016","journal-title":"BMC Pharmacol. Toxicol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"235","DOI":"10.5664\/jcsm.27492","article-title":"Drug treatment of REM sleep behavior disorder: the use of drug therapies other than clonazepam","volume":"5","author":"Anderson","year":"2009","journal-title":"J. Clin. Sleep Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.pneurobio.2016.10.001","article-title":"Insulin resistance and Parkinson\u2019s disease: a new target for disease modification?","author":"Athauda","year":"2016","journal-title":"Prog. Neurobiol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.smrv.2016.06.005","article-title":"Evidence for the efficacy of melatonin in the treatment of primary adult sleep disorders","volume":"34","author":"Auld","year":"2017","journal-title":"Sleep Med. Rev."},{"key":"B16","doi-asserted-by":"publisher","first-page":"85","DOI":"10.5664\/jcsm.27717","article-title":"Best practice guide for the treatment of REM sleep behavior disorder (RBD)","volume":"6","author":"Aurora","year":"2010","journal-title":"J. Clin. Sleep Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1176\/appi.neuropsych.12070175","article-title":"Associations of sleep disturbance symptoms with health-related quality of life in Parkinson\u2019s disease","volume":"25","author":"Avidan","year":"2013","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"B18","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1093\/brain\/aws009","article-title":"Parkinson\u2019s disease, insulin resistance and novel agents of neuroprotection","volume":"136","author":"Aviles-Olmos","year":"2013","journal-title":"Brain"},{"key":"B19","doi-asserted-by":"publisher","first-page":"535613","DOI":"10.1155\/2013\/535613","article-title":"Restless legs syndrome and its associated risk factors in Parkinson\u2019s disease","volume":"2013","author":"Azmin","year":"2013","journal-title":"Parkinsons. Dis."},{"key":"B20","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s10552-009-9497-6","article-title":"Parkinson\u2019s disease and cancer risk: a systematic review and meta-analysis","volume":"21","author":"Bajaj","year":"2010","journal-title":"Cancer Causes Control"},{"key":"B21","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jneumeth.2003.10.017","article-title":"Measurement of motor disability in MPTP-treated macaques using a telemetry system for estimating circadian motor activity","volume":"134","author":"Barcia","year":"2004","journal-title":"J. Neurosci. Methods"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.3233\/jpd-202200","article-title":"Animal models of Parkinson\u2019s disease: are they useful or not?","volume":"10","author":"Barker","year":"2020","journal-title":"J. Parkinsons. Dis."},{"key":"B23","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.brainres.2014.09.068","article-title":"Neuroprotective and antidepressant-like effects of melatonin in a rotenone-induced Parkinson\u2019s disease model in rats","volume":"1593","author":"Bassani","year":"2014","journal-title":"Brain Res."},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14774","article-title":"Exploratory pilot study of exogenous sustained\u2010release melatonin on nocturia in parkinson\u2019s disease","volume":"45","author":"Batla","year":"2021","journal-title":"Eur. J. Neurol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/j.sleep.2015.06.018","article-title":"Effect of melatonin on sleep disorders in a monkey model of Parkinson\u2019s disease","volume":"16","author":"Belaid","year":"2015","journal-title":"Sleep Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1016\/S0024-3205(00)00751-7","article-title":"Effects of bilateral striatal 6-OHDA lesions on circadian rhythms in the rat A radiotelemetric study","volume":"67","author":"Ben","year":"2000","journal-title":"Life Sci."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1007\/s00415-013-6859-5","article-title":"Nocturnal hypertension and dysautonomia in patients with Parkinson\u2019s disease: are they related?","volume":"260","author":"Berganzo","year":"2013","journal-title":"J. Neurol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S1389-9457(03)00072-8","article-title":"Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients","volume":"4","author":"Boeve","year":"2003","journal-title":"Sleep Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/nrd.2018.109","article-title":"Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing","volume":"17","author":"Boland","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"B30","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1097\/00002826-200303000-00005","article-title":"Study of circadian melatonin secretion pattern at different stages of Parkinson\u2019s disease","volume":"26","author":"Bordet","year":"2003","journal-title":"Clin. Neuropharmacol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"251","DOI":"10.3109\/07420521003664213","article-title":"Effects of l-dopa on circadian rhythms of 6-ohda striatal lesioned rats: a radiotelemetric study","volume":"27","author":"Boulamery","year":"2010","journal-title":"Chronobiol. Int."},{"key":"B32","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1001\/jamaneurol.2014.65","article-title":"Sleep and circadian rhythm regulation in early Parkinson disease","volume":"71","author":"Breen","year":"2014","journal-title":"JAMA Neurol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"999","DOI":"10.14670\/HH-28.999","article-title":"Melatonin prevents dopaminergic cell loss induced by lentiviral vectors expressing A30P mutant alpha-synuclein","volume":"28","author":"Brito-Armas","year":"2013","journal-title":"Histol. Histopathol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1007\/BF01959946","article-title":"Melatonin modulates apomorphine-induced rotational behaviour","volume":"47","author":"Burton","year":"1991","journal-title":"Experientia"},{"key":"B35","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1007\/s00415-011-6109-7","article-title":"Sleep disturbances in untreated Parkinson\u2019s disease","volume":"258","author":"Buskova","year":"2011","journal-title":"J. Neurol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/0165-1781(89)90047-4","article-title":"The Pittsburgh sleep quality index: a new instrument for psychiatric practice and research","volume":"28","author":"Buysse","year":"1989","journal-title":"Psychiatry Res."},{"key":"B37","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1111\/j.1468-1331.2009.02848.x","article-title":"Expression of clock genes Per1 and Bmal1 in total leukocytes in health and Parkinson\u2019s disease","volume":"17","author":"Cai","year":"2010","journal-title":"Eur. J. Neurol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s00702-013-1132-8","article-title":"A long-term prospective follow-up study of incident RLS in the course of chronic DAergic therapy in newly diagnosed untreated patients with Parkinson\u2019s disease","volume":"121","author":"Calzetti","year":"2014","journal-title":"J. Neural Transm."},{"key":"B39","doi-asserted-by":"publisher","first-page":"106","DOI":"10.32794\/mr11250025","article-title":"Are melatonin doses employed clinically adequate for melatonin-induced cytoprotection?","volume":"2","author":"Cardinali","year":"","journal-title":"Melatonin Res."},{"key":"B40","doi-asserted-by":"publisher","first-page":"480","DOI":"10.3389\/fendo.2019.00480","article-title":"Melatonin: clinical perspectives in neurodegeneration","volume":"10","author":"Cardinali","year":"","journal-title":"Front. Endocrinol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1586\/17446651.3.2.269","article-title":"Therapeutic potential of melatonin agonists","volume":"3","author":"Cardinali","year":"2008","journal-title":"Expert Rev. Endocrinol. Metab."},{"key":"B42","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/0014-2999(80)90025-4","article-title":"Prostaglandin E release by rat medial basal hypothalamus in vitro. Inhibition by melatonin at submicromolar concentrations","volume":"67","author":"Cardinali","year":"1980","journal-title":"Eur. J. Pharmacol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.brainres.2015.12.036","article-title":"Chronic low-dose melatonin treatment maintains nigrostriatal integrity in an intrastriatal rotenone model of Parkinson\u2019s disease","volume":"1633","author":"Carriere","year":"2016","journal-title":"Brain Res."},{"key":"B44","doi-asserted-by":"publisher","first-page":"8638","DOI":"10.3390\/ijms14048638","article-title":"Melatonin: buffering the immune system","volume":"14","author":"Carrillo-Vico","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"B45","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/S0531-5565(96)00173-8","article-title":"Melatonin levels in Parkinson\u2019s disease: drug therapy versus electrical stimulation of the internal globus pallidus","volume":"32","author":"Catal\u00e1","year":"1997","journal-title":"Exp. Gerontol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.jpain.2008.08.007","article-title":"Preoperative anxiolytic effect of melatonin and clonidine on postoperative pain and morphine consumption in patients undergoing abdominal hysterectomy: a double-blind, randomized, placebo-controlled study","volume":"10","author":"Caumo","year":"2009","journal-title":"J. Pain"},{"key":"B47","doi-asserted-by":"publisher","first-page":"3263","DOI":"10.1111\/bph.13950","article-title":"Melatonin receptors: molecular pharmacology and signalling in the context of system bias","volume":"175","author":"Cecon","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.smrv.2016.08.001","article-title":"A systematic review of the literature on disorders of sleep and wakefulness in Parkinson\u2019s disease from 2005 to 2015","volume":"35","author":"Chahine","year":"2017","journal-title":"Sleep Med. Rev."},{"key":"B49","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/j.1600-079X.2011.00945.x","article-title":"Melatonin attenuates kainic acid-induced neurotoxicity in mouse hippocampus via inhibition of autophagy and \u03b1-synuclein aggregation","volume":"52","author":"Chang","year":"2012","journal-title":"J. Pineal Res."},{"key":"B50","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/jnnp.73.6.629","article-title":"The Parkinson\u2019s disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson\u2019s disease","volume":"73","author":"Chaudhuri","year":"2002","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"B51","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1034\/j.1600-079X.2002.01871.x","article-title":"Melatonin attenuates MPP+-induced neurodegeneration and glutathione impairment in the nigrostriatal dopaminergic pathway","volume":"32","author":"Chen","year":"2002","journal-title":"J. Pineal Res."},{"key":"B52","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/ana.21995","article-title":"Clinical progression in Parkinson disease and the neurobiology of axons","volume":"67","author":"Cheng","year":"2010","journal-title":"Ann. Neurol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1254\/jphs.11183FP","article-title":"Melatonin modulates the GABAergic response in cultured rat hippocampal neurons","volume":"119","author":"Cheng","year":"2012","journal-title":"J. Pharmacol. Sci."},{"key":"B54","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/S0006-8993(97)00188-1","article-title":"Melatonin administration protects CA1 hippocampal neurons after transient forebrain ischemia in rats","volume":"755","author":"Cho","year":"1997","journal-title":"Brain Res."},{"key":"B55","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.neuchi.2015.03.002","article-title":"Melatonin: physiological effects in humans","volume":"61","author":"Claustrat","year":"2015","journal-title":"Neurochirurgie"},{"key":"B56","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1096\/fj.00-0129com","article-title":"Melatonin protects against 6\u2010OHDA\u2010induced neurotoxicity in rats: a role for mitochondrial complex I activity","volume":"15","author":"Dabbeni-Sala","year":"2001","journal-title":"FASEB J."},{"key":"B57","doi-asserted-by":"publisher","first-page":"105878","DOI":"10.1016\/j.clineuro.2020.105878","article-title":"Melatonin supplementation and the effects on clinical and metabolic status in Parkinson\u2019s disease: a randomized, double-blind, placebo-controlled trial","volume":"195","author":"Daneshvar Kakhaki","year":"2020","journal-title":"Clin. Neurol. Neurosurg."},{"key":"B58","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41572-018-0016-5","article-title":"REM sleep behaviour disorder","volume":"4","author":"Dauvilliers","year":"2018","journal-title":"Nat. Rev. Dis. Prim."},{"key":"B59","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s11357-017-0002-y","article-title":"The oxygen paradox, the French paradox, and age-related diseases","volume":"39","author":"Davies","year":"2017","journal-title":"GeroScience"},{"key":"B60","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/0163-7258(95)02020-9","article-title":"Chronobiotics - drugs that shift rhythms","volume":"69","author":"Dawson","year":"1996","journal-title":"Pharmacol. Ther."},{"key":"B61","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1002\/mds.24969","article-title":"Suggested immobilization test for diagnosis of restless legs syndrome in Parkinson\u2019s disease","volume":"27","author":"De Cock","year":"2012","journal-title":"Mov. Disord."},{"key":"B62","doi-asserted-by":"publisher","first-page":"e139","DOI":"10.1212\/WNL.0000000000005771","article-title":"Association between diabetes and subsequent Parkinson disease: a record-linkage cohort study","volume":"91","author":"De Pablo-Fernandez","year":"2018","journal-title":"Neurology"},{"key":"B63","doi-asserted-by":"publisher","first-page":"110485","DOI":"10.1016\/j.biopha.2020.110485","article-title":"Effect of melatonin administration on the PER1 and BMAL1 clock genes in patients with Parkinson\u2019s disease","volume":"129","author":"Delgado-Lara","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"B64","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1182\/blood-2005-09-3691","article-title":"Melatonin suppresses macrophage cyclooxygenase-2 and inducible nitric oxide synthase expression by inhibiting p52 acetylation and binding","volume":"108","author":"Deng","year":"2006","journal-title":"Blood"},{"key":"B65","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.neulet.2011.05.058","article-title":"Decreased expression of Bmal2 in patients with Parkinson\u2019s disease","volume":"499","author":"Ding","year":"2011","journal-title":"Neurosci. Lett."},{"key":"B66","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.sleep.2005.04.004","article-title":"Melatonin for sleep disturbances in Parkinson\u2019s disease","volume":"6","author":"Dowling","year":"2005","journal-title":"Sleep Med."},{"key":"B67","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1124\/pr.110.002832","article-title":"International union of basic and clinical pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors","volume":"62","author":"Dubocovich","year":"2010","journal-title":"Pharmacol. Rev."},{"key":"B68","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1097\/00001756-199601310-00053","article-title":"Melatonin-dopamine interaction in the striatal projection area of sensorimotor cortex in the rat","volume":"7","author":"Escames","year":"1996","journal-title":"Neuroreport"},{"key":"B69","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1111\/j.1365-2826.2004.01250.x","article-title":"Mechanisms of N-methyl-D-aspartate receptor inhibition by melatonin in the rat striatum","volume":"16","author":"Escames","year":"2004","journal-title":"J. Neuroendocrinol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1176\/appi.focus.16101","article-title":"Meta-Analysis: melatonin for the treatment of primary sleep disorders","volume":"16","author":"Ferracioli-Oda","year":"2018","journal-title":"Focus (Madison)"},{"key":"B71","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/BF02257677","article-title":"Circadian secretion pattern of melatonin in de novo Parkinsonian patients: evidence for phase-shifting properties of l-dopa","volume":"5","author":"Fertl","year":"1993","journal-title":"J. Neural Transm. - Park. Dis. Dement. Sect."},{"key":"B72","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.nbd.2014.08.024","article-title":"Loss of dopamine disrupts circadian rhythms in a mouse model of Parkinson\u2019s disease","volume":"71","author":"Fifel","year":"2014","journal-title":"Neurobiol. Dis."},{"key":"B73","doi-asserted-by":"publisher","first-page":"e86240","DOI":"10.1371\/journal.pone.0086240","article-title":"Alteration of daily and circadian rhythms following dopamine depletion in MPTP treated non-human primates","volume":"9","author":"Fifel","year":"2014","journal-title":"PLoS One"},{"key":"B74","doi-asserted-by":"publisher","first-page":"23","DOI":"10.2174\/1874360900901010023","article-title":"Neuroprotective effect of melatonin on glucocorticoid toxicity in the rat hippocampus","volume":"1","author":"Furio","year":"2014","journal-title":"Open Physiol. J."},{"key":"B75","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1002\/mds.23394","article-title":"What are the most important nonmotor symptoms in patients with Parkinson\u2019s disease and are we missing them?","volume":"25","author":"Gallagher","year":"2010","journal-title":"Mov. Disord."},{"key":"B76","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1111\/jpi.12134","article-title":"Melatonin as a potential therapy for sepsis: a phase i dose escalation study and an ex vivo whole blood model under conditions of sepsis","volume":"56","author":"Galley","year":"2014","journal-title":"J. Pineal Res."},{"key":"B77","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.encep.2019.04.068","article-title":"The use of melatonin in adult psychiatric disorders: expert recommendations by the French institute of medical research on sleep (SFRMS)","volume":"45","author":"Geoffroy","year":"2019","journal-title":"Encephale"},{"key":"B78","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1002\/mds.27886","article-title":"Melatonin for rapid eye movement sleep behavior disorder in Parkinson\u2019s disease: a randomised controlled trial","volume":"35","author":"Gilat","year":"2020","journal-title":"Mov. Disord."},{"key":"B79","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1096\/fasebj.10.8.8666166","article-title":"Neuroprotection by melatonin from kainate\u2010induced excitotoxicity in rats","volume":"10","author":"Giusti","year":"1996","journal-title":"FASEB J."},{"key":"B80","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1136\/jnnp.2006.100370","article-title":"Insomnia in Parkinson\u2019s disease: frequency and progression over time","volume":"78","author":"Gjerstad","year":"2007","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"B81","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/0149-7634(95)00052-6","article-title":"Melatonin effects on behavior: possible mediation by the central GABAergic system","volume":"20","author":"Golombek","year":"1996","journal-title":"Neurosci. Biobehav. Rev."},{"key":"B82","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1002\/mds.20874","article-title":"Sleep complaints and their relation with drug treatment in patients suffering from Parkinson\u2019s disease","volume":"21","author":"G\u00f3mez-Esteban","year":"2006","journal-title":"Mov. Disord."},{"key":"B83","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5402\/2012\/360379","article-title":"Effect of chronic L-dopa or melatonin treatments after dopamine deafferentation in rats: dyskinesia, motor performance, and cytological analysis","volume":"2012","author":"Gutierrez-Valdez","year":"2012","journal-title":"ISRN Neurol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1111\/j.1365-2869.2007.00570.x","article-title":"Measurement properties and hierarchical item structure of the Epworth sleepiness scale in Parkinson\u2019s disease","volume":"16","author":"Hagell","year":"2007","journal-title":"J. Sleep Res."},{"key":"B85","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.pneurobio.2010.12.004","article-title":"Melatonin-A pleiotropic, orchestrating regulator molecule","volume":"93","author":"Hardeland","year":"2011","journal-title":"Prog. Neurobiol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"e12525","DOI":"10.1111\/jpi.12525","article-title":"Melatonin and inflammation\u2014story of a double-edged blade","volume":"65","author":"Hardeland","year":"","journal-title":"J. Pineal Res."},{"key":"B87","doi-asserted-by":"publisher","first-page":"102","DOI":"10.2174\/1871524918666180531083944","article-title":"Recent findings in melatonin research and their relevance to the CNS","volume":"18","author":"Hardeland","year":"","journal-title":"Cent. Nerv. Syst. Agents Med. Chem."},{"key":"B88","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S0197-4580(97)80309-0","article-title":"Twenty-four hour cortisol release profiles in patients with Alzheimer\u2019s and Parkinson\u2019s disease compared to normal controls: ultr1adian secretory pulsatility and diurnal variation","volume":"18","author":"Hartmann","year":"1997","journal-title":"Neurobiol. Aging"},{"key":"B89","doi-asserted-by":"publisher","first-page":"427810","DOI":"10.4061\/2010\/427810","article-title":"Subtle cardiovascular dysfunction in the unilateral 6-hydroxydopamine- lesioned rat","volume":"2010","author":"Henderson","year":"2010","journal-title":"Parkinsons. Dis."},{"key":"B90","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1002\/mds.23190","article-title":"Scales to assess sleep impairment in Parkinson\u2019s disease: critique and recommendations","volume":"25","author":"H\u00f6gl","year":"2010","journal-title":"Mov. Disord."},{"key":"B91","doi-asserted-by":"publisher","first-page":"14046","DOI":"10.1523\/JNEUROSCI.2128-10.2010","article-title":"Endogenous dopamine regulates the rhythm of expression of the clock protein PER2 in the rat dorsal striatum via daily activation of D2 dopamine receptors","volume":"30","author":"Hood","year":"2010","journal-title":"J. Neurosci."},{"key":"B92","doi-asserted-by":"publisher","first-page":"12473","DOI":"10.1073\/pnas.1610371113","article-title":"Cross-talk between amyloidogenic proteins in type-2 diabetes and Parkinson\u2019s disease","volume":"113","author":"Horvath","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B93","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/bpa.12369","article-title":"Expression of aquaporin 1 and aquaporin 4 in the temporal neocortex of patients with Parkinson\u2019s disease","volume":"27","author":"Hoshi","year":"2017","journal-title":"Brain Pathol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1111\/j.1471-4159.2009.06061.x","article-title":"Fibroblast growth factor 9 prevents MPP+-induced death of dopaminergic neurons and is involved in melatonin neuroprotection in vivo and in vitro","volume":"109","author":"Huang","year":"2009","journal-title":"J. Neurochem."},{"key":"B95","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12868-019-0522-8","article-title":"Comparative study of striatum GABA concentrations and magnetic resonance spectroscopic imaging in Parkinson\u2019s disease monkeys","volume":"20","author":"Huang","year":"2019","journal-title":"BMC Neurosci."},{"key":"B96","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1517\/17425255.2014.934671","article-title":"The application of allometric scaling principles to predict pharmacokinetic parameters across species","volume":"10","author":"Huang","year":"2014","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.neulet.2012.01.040","article-title":"Melatonin modulates cytoskeletal organization in the rat brain hippocampus","volume":"511","author":"Jim\u00e9nez-Rubio","year":"2012","journal-title":"Neurosci. Lett."},{"key":"B98","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0304-3940(98)00170-0","article-title":"Melatonin protects nigral dopaminergic neurons from 1-methyl-4- phenylpyridinium (MPP+) neurotoxicity in rats","volume":"245","author":"Jin","year":"1998","journal-title":"Neurosci. Lett."},{"key":"B99","doi-asserted-by":"publisher","first-page":"4123","DOI":"10.1097\/00001756-199812210-00022","article-title":"Melatonin increases striatal dopaminergic function in 6-OHDA-lesioned rats","volume":"9","author":"Joo","year":"1998","journal-title":"Neuroreport"},{"key":"B100","doi-asserted-by":"publisher","first-page":"105028","DOI":"10.1016\/j.nbd.2020.105028","article-title":"Microglia and astrocyte dysfunction in Parkinson\u2019s disease","volume":"144","author":"Kam","year":"2020","journal-title":"Neurobiol. Dis."},{"key":"B101","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0197-4580(02)00133-1","article-title":"Synergistic effects of melatonin and deprenyl against MPTP-induced mitochondrial damage and DA depletion","volume":"24","author":"Khaldy","year":"2003","journal-title":"Neurobiol. Aging"},{"key":"B102","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1097\/00001756-199807130-00043","article-title":"Melatonin protects 6-OHDA-induced neuronal death of nigrostriatal dopaminergic system","volume":"9","author":"Kim","year":"1998","journal-title":"Neuroreport"},{"key":"B103","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.expneurol.2011.08.003","article-title":"Circadian dysfunction in a mouse model of Parkinson\u2019s disease","volume":"232","author":"Kudo","year":"2011","journal-title":"Exp. Neurol."},{"key":"B104","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1002\/1531-8257(199905)14:3<507::AID-MDS1021>3.0.CO;2-8","article-title":"Melatonin as a therapy in REM sleep behavior disorder patients: an open-labeled pilot study on the possible influence of melatonin on REM-sleep regulation","volume":"14","author":"Kunz","year":"1999","journal-title":"Mov. Disord."},{"key":"B105","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1159\/000119383","article-title":"Melatonin effects in a patient with severe REM sleep behavior disorder: case report and theoretical considerations","volume":"36","author":"Kunz","year":"1997","journal-title":"Neuropsychobiology"},{"key":"B106","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1159\/000488893","article-title":"Twenty years after: another case report of melatonin effects on REM sleep behavior disorder, using serial dopamine transporter imaging","volume":"76","author":"Kunz","year":"2018","journal-title":"Neuropsychobiology"},{"key":"B107","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1111\/j.1365-2869.2010.00848.x","article-title":"A two-part, double-blind, placebo-controlled trial of exogenous melatonin in REM sleep behaviour disorder","volume":"19","author":"Kunz","year":"2010","journal-title":"J. Sleep Res."},{"key":"B108","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1177\/074873049701200622","article-title":"Melatonin: role in gating nocturnal rise in sleep propensity","volume":"12","author":"Lavie","year":"1997","journal-title":"J. Biol. Rhythms"},{"key":"B109","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3109\/07420528.2011.649870","article-title":"Circadian dysfunction in a rotenone-induced parkinsonian rodent model","volume":"29","author":"Lax","year":"2012","journal-title":"Chronobiol. Int."},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1111\/jpi.12456","article-title":"Neuroprotective effects of melatonin on amphetamine-induced dopaminergic fiber degeneration in the hippocampus of postnatal rats","volume":"64","author":"Leeboonngam","year":"2018","journal-title":"J. Pineal Res."},{"key":"B111","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.bbr.2004.03.004","article-title":"Effects of blocking the dopamine biosynthesis and of neurotoxic dopamine depletion with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on voluntary wheel running in mice","volume":"154","author":"Leng","year":"2004","journal-title":"Behav. Brain Res."},{"key":"B112","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1080\/07420520500545862","article-title":"Circadian uses of melatonin in humans","volume":"23","author":"Lewy","year":"2006","journal-title":"Chronobiol Int."},{"key":"B113","first-page":"561","article-title":"Assessment and treatment of chronobiologic disorders using plasma melatonin levels and bright light exposure: the clock-gate model and the phase response curve","volume":"20","author":"Lewy","year":"1984","journal-title":"Psychopharmacol. Bull."},{"key":"B114","doi-asserted-by":"publisher","first-page":"505","DOI":"10.3389\/fnins.2020.00505","article-title":"Elevated plasma melatonin levels are correlated with the non-motor symptoms in Parkinson\u2019s disease: a cross-sectional study","volume":"14","author":"Li","year":"2020","journal-title":"Front. Neurosci."},{"key":"B115","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.yfrne.2018.06.004","article-title":"Exogenous melatonin as a treatment for secondary sleep disorders: a systematic review and meta-analysis","volume":"52","author":"Li","year":"2019","journal-title":"Front. Neuroendocrinol."},{"key":"B116","doi-asserted-by":"publisher","first-page":"2726","DOI":"10.4103\/0366-6999.218025","article-title":"Effects of melatonin levels on neurotoxicity of the medial prefrontal cortex in a rat model of Parkinson\u2019s disease","volume":"130","author":"Li","year":"2017","journal-title":"Chin. Med. J. (Engl)."},{"key":"B117","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/j.1600-079X.2007.00456.x","article-title":"Melatonin attenuates arsenite-induced apoptosis in rat brain: involvement of mitochondrial and endoplasmic reticulum pathways and aggregation of \u03b1-synuclein","volume":"43","author":"Lin","year":"2007","journal-title":"J. Pineal Res."},{"key":"B118","first-page":"26","article-title":"[Sleep disorders in Parkinson\u2019s disease without dementia: a comparative randomized controlled study of melatonin and clonazepam]","volume":"112","author":"Litvinenko","year":"2012","journal-title":"Zh. Nevrol. Psikhiatr. Im. S. S. Korsakova"},{"key":"B119","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jns.2007.09.033","article-title":"Case-control study of restless legs syndrome and quality of sleep in Parkinson\u2019s disease","volume":"266","author":"Loo","year":"2008","journal-title":"J. Neurol. Sci."},{"key":"B120","doi-asserted-by":"publisher","first-page":"e0183090","DOI":"10.1371\/journal.pone.0183090","article-title":"Mitochondrial impairment and melatonin protection in parkinsonian mice do not depend of inducible or neuronal nitric oxide synthases","volume":"12","author":"L\u00f3pez","year":"2017","journal-title":"PLoS One"},{"key":"B121","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1096\/fj.03-0739com","article-title":"Taurine prevents the neurotoxicity of \u03b2\u2010amyloid and glutamate receptor agonists: activation of GABA receptors and possible implications for Alzheimer\u2019s disease and other neurological disorders","volume":"18","author":"Louzada","year":"2004","journal-title":"FASEB J."},{"key":"B122","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1038\/s41467-018-03802-y","article-title":"GABAergic inhibition in dual-transmission cholinergic and GABAergic striatal interneurons is abolished in Parkinson disease","volume":"9","author":"Lozovaya","year":"2018","journal-title":"Nat. Commun."},{"key":"B123","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1093\/sleep\/26.8.1049","article-title":"Assessment of sleep and sleepiness in Parkinson disease","volume":"26","author":"Marinus","year":"2003","journal-title":"Sleep"},{"key":"B124","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s00702-017-1720-0","article-title":"\u03b1-Synuclein nonhuman primate models of Parkinson\u2019s disease","volume":"125","author":"Marmion","year":"2018","journal-title":"J. Neural Transm."},{"key":"B125","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s00401-018-1832-0","article-title":"Interaction of amyloidogenic proteins in pancreatic \u03b2 cells from subjects with synucleinopathies","volume":"135","author":"Martinez-Valbuena","year":"2018","journal-title":"Acta Neuropathol."},{"key":"B126","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.sleep.2012.09.018","article-title":"Treatment outcomes in REM sleep behavior disorder","volume":"14","author":"McCarter","year":"2013","journal-title":"Sleep Med."},{"key":"B127","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s00415-006-0390-x","article-title":"Effect of exogenous melatonin on sleep and motor dysfunction in Parkinson\u2019s disease: a randomized, double blind, placebo-controlled study","volume":"254","author":"Medeiros","year":"2007","journal-title":"J. Neurol."},{"key":"B128","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.neuron.2016.03.038","article-title":"Understanding dopaminergic cell death pathways in Parkinson disease","volume":"90","author":"Michel","year":"2016","journal-title":"Neuron"},{"key":"B129","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s00702-020-02149-3","article-title":"Parkinson\u2019s disease and iron","volume":"127","author":"Mochizuki","year":"2020","journal-title":"J. Neural Transm."},{"key":"B130","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/j.clinthera.2012.03.001","article-title":"The effect of levodopa on pulmonary function in Parkinson\u2019s disease: a systematic review and meta-analysis","volume":"34","author":"Monteiro","year":"2012","journal-title":"Clin. Ther."},{"key":"B131","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1111\/jpi.12212","article-title":"Melatonin enhances L-DOPA therapeutic effects, helps to reduce its dose, and protects dopaminergic neurons in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice","volume":"58","author":"Naskar","year":"2015","journal-title":"J. Pineal Res."},{"key":"B132","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.5664\/jcsm.3148","article-title":"Effects of sleep disorders on the non-motor symptoms of Parkinson disease","volume":"9","author":"Neikrug","year":"2013","journal-title":"J. Clin. Sleep Med."},{"key":"B133","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1007\/s00429-017-1439-6","article-title":"Melatonin receptors: distribution in mammalian brain and their respective putative functions","volume":"222","author":"Ng","year":"2017","journal-title":"Brain Struct. Funct."},{"key":"B134","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.3233\/JPD-181472","article-title":"Non-dopaminergic therapies","volume":"8","author":"Nutt","year":"2018","journal-title":"J. Parkinsons. Dis."},{"key":"B135","doi-asserted-by":"publisher","first-page":"S72","DOI":"10.24875\/GMM.M000008","article-title":"Efecto de la administraci\u00f3n de melatonina sobre la actividad de la ciclooxigenasa-2, la concentraci\u00f3n s\u00e9rica de metabolitos del \u00f3xido n\u00edtrico, los lipoper\u00f3xidos y la actividad de la glutati\u00f3n peroxidasa en pacientes con enfermedad de Parkinson","volume":"153","author":"Ortiz","year":"2017","journal-title":"Gac. Med. Mex."},{"key":"B136","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1176\/appi.neuropsych.11100315","article-title":"Motor and non-motor symptoms in Turkish patients with Parkinson\u2019s disease affecting family caregiver burden and quality of life","volume":"24","author":"Ozdilek","year":"2012","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"B137","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.3109\/10715762.2015.1027198","article-title":"Melatonin is protective against 6-hydroxydopamine-induced oxidative stress in a hemiparkinsonian rat model","volume":"49","author":"Ozsoy","year":"2015","journal-title":"Free Radic. Res."},{"key":"B138","doi-asserted-by":"publisher","first-page":"806","DOI":"10.3389\/fneur.2018.00806","article-title":"Beyond dopamine: GABA, glutamate, and the axial symptoms of Parkinson disease","volume":"9","author":"O\u2019Gorman Tuura","year":"2018","journal-title":"Front. Neurol."},{"key":"B139","doi-asserted-by":"publisher","first-page":"558","DOI":"10.3389\/fpsyt.2020.00558","article-title":"Expert opinions and consensus recommendations for the evaluation and management of insomnia in clinical practice: joint statements of five Italian scientific societies","volume":"11","author":"Palagini","year":"2020","journal-title":"Front. Psychiatry"},{"key":"B140","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.pneurobio.2008.04.001","article-title":"Physiological effects of melatonin: role of melatonin receptors and signal transduction pathways","volume":"85","author":"Pandi-Perumal","year":"2008","journal-title":"Prog. Neurobiol."},{"key":"B141","doi-asserted-by":"publisher","first-page":"637","DOI":"10.2174\/1567205015666180411092551","article-title":"Melatonin treatment enhances a\u03b2 lymphatic clearance in a transgenic mouse model of amyloidosis","volume":"15","author":"Pappolla","year":"2018","journal-title":"Curr. Alzheimer Res."},{"key":"B142","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.pbb.2011.06.026","article-title":"Melatonin protects against neurobehavioral and mitochondrial deficits in a chronic mouse model of Parkinson\u2019s disease","volume":"99","author":"Patki","year":"2011","journal-title":"Pharmacol. Biochem. Behav."},{"key":"B143","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.lfs.2017.11.016","article-title":"Melatonin protects against behavioral deficits, dopamine loss and oxidative stress in homocysteine model of Parkinson\u2019s disease","volume":"192","author":"Paul","year":"2018","journal-title":"Life Sci."},{"key":"B144","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.parkreldis.2014.04.023","article-title":"Gender differences in non-motor symptoms in early Parkinson\u2019s disease: a 2-years follow-up study on previously untreated patients","volume":"20","author":"Picillo","year":"2014","journal-title":"Park. Relat. Disord."},{"key":"B145","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1111\/j.1742-1241.2008.01869.x","article-title":"Diagnosis and management of Parkinson\u2019s disease dementia","volume":"62","author":"Poewe","year":"2008","journal-title":"Int. J. Clin. Pract."},{"key":"B146","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/j.1468-1331.2007.01998.x","article-title":"The frequency and nature of sleep disorders in a community-based population of patients with Parkinson\u2019s disease","volume":"15","author":"Porter","year":"2008","journal-title":"Eur. J. Neurol."},{"key":"B147","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.jns.2013.01.039","article-title":"Association of pain, Parkinson\u2019s disease, and restless legs syndrome","volume":"327","author":"Rana","year":"2013","journal-title":"J. Neurol. Sci."},{"key":"B148","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1179\/1743132813Y.0000000264","article-title":"Prevalence of nocturia in Parkinson\u2019s disease patients from various ethnicities","volume":"36","author":"Rana","year":"2014","journal-title":"Neurol. Res."},{"key":"B149","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1615\/JEnvironPatholToxicolOncol.2018025666","article-title":"Melatonin improves behavioral and biochemical outcomes in a rotenone-induced rat model of Parkinson\u2019s disease","volume":"37","author":"Rasheed","year":"2018","journal-title":"J. Environ. Pathol. Toxicol. Oncol."},{"key":"B150","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1096\/fj.07-9574lsf","article-title":"Dose translation from animal to human studies revisited","volume":"22","author":"Reagan\u2010Shaw","year":"2008","journal-title":"FASEB J."},{"key":"B151","doi-asserted-by":"publisher","first-page":"3863","DOI":"10.1007\/s00018-017-2609-7","article-title":"Melatonin as a mitochondria-targeted antioxidant: one of evolution\u2019s best ideas","volume":"74","author":"Reiter","year":"2017","journal-title":"Cel. Mol. Life Sci."},{"key":"B152","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1097\/YCO.0b013e328017f6b1","article-title":"Tardive dyskinesia: eliminated, forgotten, or overshadowed?","volume":"20","author":"Remington","year":"2007","journal-title":"Curr. Opin. Psychiatry"},{"key":"B153","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0003-9993(96)90216-6","article-title":"Obstructive and restrictive pulmonary dysfunction increases disability in Parkinson disease","volume":"77","author":"Sabat\u00e9","year":"1996","journal-title":"Arch. Phys. Med. Rehabil."},{"key":"B154","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/j.1600-079X.2006.00412.x","article-title":"Melatonin protects against rotenone-induced oxidative stress in a hemiparkinsonian rat model","volume":"42","author":"Saravanan","year":"2007","journal-title":"J. Pineal Res."},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.2174\/1567205014666170523094938","article-title":"Melatonin effects in REM sleep behavior disorder associated with obstructive sleep apnea syndrome: a case series","volume":"14","author":"Schaefer","year":"2017","journal-title":"Curr. Alzheimer Res."},{"key":"B156","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.parkreldis.2018.10.018","article-title":"CSF \u03b1-synuclein inversely correlates with non-motor symptoms in a cohort of PD patients","volume":"61","author":"Schirinzi","year":"2019","journal-title":"Park. Relat. Disord."},{"key":"B157","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.brainres.2005.10.084","article-title":"Physiological neuroprotection by melatonin in a 6-hydroxydopamine model of Parkinson\u2019s disease","volume":"1068","author":"Sharma","year":"2006","journal-title":"Brain Res."},{"key":"B158","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/nyas.14005","article-title":"The role of melatonin in targeting cell signaling pathways in neurodegeneration","volume":"1443","author":"Shukla","year":"2019","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"B159","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/S0014-2999(00)00422-2","article-title":"Effects of a seven-day continuous infusion of L-DOPA on daily rhythms in the rat","volume":"401","author":"Simon","year":"2000","journal-title":"Eur. J. Pharmacol."},{"key":"B160","doi-asserted-by":"publisher","first-page":"3133","DOI":"10.1007\/s11033-020-05354-1","article-title":"Neurodegeneration by oxidative stress: a review on prospective use of small molecules for neuroprotection","volume":"47","author":"Singh","year":"2020","journal-title":"Mol. Biol. Rep."},{"key":"B161","first-page":"419","article-title":"Neuroprotection of the nigrostriatal dopaminergic neurons by melatonin in hemiparkinsonium rat","volume":"124","author":"Singh","year":"2006","journal-title":"Indian J. Med. Res."},{"key":"B162","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/j.1600-079X.2010.00819.x","article-title":"Melatonin or silymarin reduces maneb- and paraquat-induced Parkinsons disease phenotype in the mouse","volume":"50","author":"Singhal","year":"2011","journal-title":"J. Pineal Res."},{"key":"B163","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1212\/WNL.0b013e31822e560e","article-title":"Associated factors for REM sleep behavior disorder in Parkinson disease","volume":"77","author":"Sixel-D\u00f6ring","year":"2011","journal-title":"Neurology"},{"key":"B164","first-page":"587","article-title":"Psychopharmacological effects of melatonin in mouse and rat","volume":"227","author":"Sugden","year":"1983","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B165","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.neubiorev.2019.05.016","article-title":"Establishing a framework for neuropathological correlates and glymphatic system functioning in Parkinson\u2019s disease","volume":"103","author":"Sundaram","year":"2019","journal-title":"Neurosci. Biobehav. Rev."},{"key":"B166","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1046\/j.1440-1819.2001.00854.x","article-title":"Melatonin therapy for REM sleep behavior disorder","volume":"55","author":"Takeuchi","year":"2001","journal-title":"Psychiatry Clin Neurosci."},{"key":"B167","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s10571-019-00720-5","article-title":"Melatonin and Parkinson disease: current status and future perspectives for molecular mechanisms","volume":"40","author":"Tamtaji","year":"2020","journal-title":"Cell. Mol. Neurobiol."},{"key":"B168","doi-asserted-by":"publisher","first-page":"44","DOI":"10.32794\/mr11250011","article-title":"Mitochondria: the birth place, battle ground and the site of melatonin metabolism in cells","volume":"2","author":"Tan","year":"2019","journal-title":"Melatonin Res."},{"key":"B169","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s10571-019-00724-1","article-title":"Pharmacological effects of melatonin as neuroprotectant in rodent model: a review on the current biological evidence","volume":"40","author":"Tan","year":"2020","journal-title":"Cel. Mol. Neurobiol."},{"key":"B170","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.1002\/jnr.22123","article-title":"Melatonin and its brain metabolite N1-acetyl-5-methoxykynuramine prevent mitochondrial nitric oxide synthase induction in Parkinsonian mice","volume":"87","author":"Tapias","year":"2009","journal-title":"J. Neurosci. Res."},{"key":"B171","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1002\/mds.23476","article-title":"Parkinson\u2019s disease sleep scale-validation of the revised version PDSS-2","volume":"26","author":"Trenkwalder","year":"2011","journal-title":"Mov. Disord."},{"key":"B172","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s00702-017-1686-y","article-title":"Epidemiology of Parkinson\u2019s disease","volume":"124","author":"Tysnes","year":"2017","journal-title":"J. Neural Transm."},{"key":"B173","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.molbrainres.2005.01.002","article-title":"The regional and cellular expression profile of the melatonin receptor MT1 in the central dopaminergic system","volume":"136","author":"Uz","year":"2005","journal-title":"Mol. Brain Res."},{"key":"B174","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.neurol.2020.06.009","article-title":"Melatonin (MEL) and its use in neurological diseases and insomnia: recommendations of the French medical and research sleep society (SFRMS)","volume":"177","author":"Vecchierini","year":"2020","journal-title":"Rev. Neurol."},{"key":"B175","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1111\/jpi.12019","article-title":"Analysis of the daily changes of melatonin receptors in the rat liver","volume":"54","author":"Venegas","year":"2013","journal-title":"J. Pineal Res."},{"key":"B176","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1001\/jamaneurol.2013.6239","article-title":"Circadian melatonin rhythm and excessive daytime sleepiness in Parkinson disease","volume":"71","author":"Videnovic","year":"2014","journal-title":"JAMA Neurol."},{"key":"B177","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/S0031-9384(99)00023-2","article-title":"A therapeutic role for melatonin antagonism in experimental models of Parkinson\u2019s disease","volume":"66","author":"Willis","year":"1999","journal-title":"Physiol. Behav."},{"key":"B178","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.brainres.2017.09.027","article-title":"Emerging preclinical interest concerning the role of circadian function in Parkinson\u2019s disease","volume":"1678","author":"Willis","year":"2018","journal-title":"Brain Res."},{"key":"B179","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.bbr.2008.04.017","article-title":"Compromised circadian function in Parkinson\u2019s disease: enucleation augments disease severity in the unilateral model","volume":"193","author":"Willis","year":"2008","journal-title":"Behav. Brain Res."},{"key":"B180","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1080\/07420520701420717","article-title":"Primary and secondary features of Parkinson\u2019s disease improve with strategic exposure to bright light: a case series study","volume":"24","author":"Willis","year":"2007","journal-title":"Chronobiol. Int."},{"key":"B181","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1177\/0269881110379307","article-title":"British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders","volume":"24","author":"Wilson","year":"2010","journal-title":"J. Psychopharmacol."},{"key":"B182","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1002\/nau.20193","article-title":"Prevalence of bladder dysfunction in Parkinsons disease","volume":"25","author":"Winge","year":"2006","journal-title":"Neurourol. Urodyn."},{"key":"B183","doi-asserted-by":"publisher","first-page":"369","DOI":"10.5665\/sleep.3416","article-title":"Restless legs syndrome: an early clinical feature of Parkinson disease in men","volume":"37","author":"Wong","year":"2014","journal-title":"Sleep"},{"key":"B184","doi-asserted-by":"publisher","first-page":"878","DOI":"10.3760\/cma.j.issn.0366-6999.20132695","article-title":"Urodynamic analysis and treatment of male Parkinson\u2019s disease patients with voiding dysfunction","volume":"127","author":"Xue","year":"2014","journal-title":"Chin. Med. J."},{"key":"B185","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neuint.2014.09.005","article-title":"Mechanism of the beneficial effect of melatonin in experimental Parkinson\u2019s disease","volume":"79","author":"Yildirim","year":"2014","journal-title":"Neurochem. Int."},{"key":"B186","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1016\/S1734-1140(13)71479-8","article-title":"Antioxidant potential of melatonin enhances the response to L-dopa in 1-methyl 4-phenyl 1,2,3,6-tetrahydropyridine-parkinsonian mice","volume":"65","author":"Zaitone","year":"2013","journal-title":"Pharmacol. Rep."},{"key":"B187","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1159\/000127185","article-title":"Inhibitory effect of melatonin on gonadotropin-releasing hormone-induced Ca2+ Oscillations in pituitary cells of newborn rats","volume":"65","author":"Zemkov\u00e1","year":"1997","journal-title":"Neuroendocrinology"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0072661","article-title":"The relationship between thermoregulation and REM sleep behaviour disorder in Parkinson\u2019s disease","volume":"8","author":"Zhong","year":"2013","journal-title":"PLoS One"},{"key":"B189","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/0006-8993(82)90157-3","article-title":"Inhibition of dopamine release by melatonin: regional distribution in the rat brain","volume":"246","author":"Zisapel","year":"1982","journal-title":"Brain Res."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.650597\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T00:41:33Z","timestamp":1618533693000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.650597\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,15]]},"references-count":189,"alternative-id":["10.3389\/fphar.2021.650597"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.650597","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,15]]},"article-number":"650597"}}